Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 13/20 | 0.55 |
| ▸ | GSK3B | P49841 | 5/20 | 0.55 |
| ▸ | JAK3 | P52333 | 4/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488997 | 0.86 | AKT2 (0.58) | AKT2GSK3BJAK3HTR2CAKT1 | |
| SCHEMBL3490600 | 0.85 | AKT2 (0.51) | AKT2GSK3BJAK3HTR2CAKT1 | |
| SCHEMBL3489710 | 0.84 | AKT2 (0.48) | AKT2GSK3BJAK3HTR2CAKT1 | |
| SCHEMBL14162138 | 0.84 | AKT2 (0.67) | AKT2GSK3BJAK3AKT1ROCK2 | |
| SCHEMBL3491379 | 0.83 | AKT2 (0.57) | AKT2GSK3BJAK3HTR2CAKT1 | |
| SCHEMBL3490604 | 0.83 | AKT2 (0.54) | AKT2GSK3BJAK3HTR2CAKT1 | |
| SCHEMBL3490533 | 0.82 | AKT2 (0.55) | AKT2GSK3BJAK3HTR2CAKT1 | |
| SCHEMBL3489802 | 0.82 | AKT2 (0.61) | AKT2GSK3BJAK3AKT1CYP2C9 | |
| SCHEMBL3491231 | 0.81 | AKT2 (0.66) | AKT2GSK3BAKT1ROCK2AKT3 | |
| SCHEMBL3491176 | 0.81 | AKT2 (0.56) | AKT2GSK3BJAK3HTR2CAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | AKT2 35/4885GSK3B 300/4885JAK3 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.